ARTICLE | Clinical News
HuMax-CD4 human antibody against CD4 regulatory update
May 31, 2004 7:00 AM UTC
The EMEA granted Orphan Drug designation for HuMax-CD4 to treat cutaneous T cell lymphoma (CTCL). The antibody is in Phase II testing. Eisai G. Ltd. (Tokyo, Japan) holds European rights to HuMax-CD4. ...